Advocacy Groups Say POM Claims Prey On Consumer Desperation
This article was originally published in The Tan Sheet
Executive Summary
“Consumers may be desperate to find a cure or treatment for their disease when conventional treatment has not worked … and turn to food products or dietary supplements,” CSPI and Public Citizen attorneys say in an amicus brief supporting FTC’s enforcement against POM.
You may also be interested in...
Supplement Industry Critics On Agenda For FDA's Ingredient List Meeting
FDAs Oct. 3 meeting agenda includes Pieter Cohen, Harvard Medical School professor; Consumers Union Programs Director Chuck Bell; Laura MacCleery, Center for Science in the Public Interest regulatory affairs director; and Stephanie Scarmo, Pew Charitable Trusts Health Care Products Project officer.
POM Wonderful Asks Court To Vacate “Draconian” FTC Order
The nearly three-year battle between FTC and POM Wonderful moves to a federal appeals court, where the pomegranate juice and supplement firm asks the judges to nix the commission’s order that POM conduct two randomized controlled trials to support disease-related health claims.
Jurors' Answers In FTC Complaint Against Prevagen Might Form A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.